title: The biosimilar insulin landscape: current developments.
abstract: Biosimilar insulins have the potential to increase access to treatment among patients with diabetes mellitus, reduce treatment costs, and expand market competition. The patents for several insulins are soon to expire, meaning there is room for copies of these products--or 'biosimilars'--to join the marketplace. It is vital that similar safety and efficacy to the innovator product is demonstrated for biosimilars. This presents many possible manufacturing and regulatory challenges. Complex manufacturing processes mean that even small differences between manufacturers can have a potential impact on the final product. Several companies are currently developing biosimilar insulins or are already producing these products in emerging markets with different regulatory requirements. For insulin biosimilars to be licensed in more established markets, manufacturers will need to meet the rigid criteria set out by agencies such as the European Medicines Agency and US Food and Drug Administration, and fulfill several pre-clinical, clinical, and pharmacovigilance surveillance criteria. As a result of differing regulatory requirements, there are possible gaps in the publically available clinical data to support the safety and efficacy of biosimilar insulins from around the world current as of July 2014. This review summarizes the current biosimilar insulin landscape.
authors.affiliation: Universidad Autonoma de Nuevo Leon, Monterrey, Mexico. drfernandolavalle@hotmail.com.
authors.forename: Fernando J
authors.initials: FJ
authors.lastname: Lavalle-González
authors.forename: Hootan
authors.initials: H
authors.lastname: Khatami
mesh_terms: D059451:Biosimilar Pharmaceuticals; D055808:Drug Discovery; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D007880:Legislation, Drug
chemical_list: D059451:Biosimilar Pharmaceuticals; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting